PTJ
TLIS

Paul Tudor Jones’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Paul Tudor Jones’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,667
Closed -$906K – 3139
2021
Q3 		$906K Buy
+9,667
New +$1.29M 0.01% 1233

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Paul Tudor Jones's TLIS Position: Q3 2023 in Review

Paul Tudor Jones sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2023, closing a stake of 667 shares — an estimated $4.8K sold.

Paul Tudor Jones first reported a position in TLIS in Q1 2021 and held it in 8 quarters. The position peaked at $129K in Q1 2021. 19 funds tracked by Wall St. Rank hold TLIS as of Q3 2023.

  • Paul Tudor Jones reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2023 after selling out during the quarter.
  • Paul Tudor Jones sold 667 Talis Biomedical Corporation Common Stock shares in Q3 2023, an estimated $4.8K.
  • Paul Tudor Jones first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 8 quarters.
  • Paul Tudor Jones's Talis Biomedical Corporation Common Stock position peaked at $129K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2023.

Based on Tudor Investment Corp's 13F filing for Q3 2023, filed 15 Nov 2023.